Gracell Biotechnologies Inc. (GRCL): Price and Financial Metrics
GET POWR RATINGS... FREE!
GRCL Stock Price Chart Interactive Chart >
GRCL Price/Volume Stats
|Current price||$2.14||52-week high||$5.69|
|Prev. close||$2.17||52-week low||$1.68|
|Day high||$2.19||Avg. volume||161,382|
|50-day MA||$2.65||Dividend yield||N/A|
|200-day MA||$3.08||Market Cap||144.85M|
Gracell Biotechnologies Inc. (GRCL) Company Bio
Gracell Biotechnologies Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing cell therapies to address medical needs in the treatment of cancer. Gracell Biotechnologies aims to disrupt conventional approaches to CAR-T cell therapies with technology platforms-FasTCAR and TruUCAR.
Most Popular Stories View All
GRCL Latest News Stream
|Loading, please wait...|
GRCL Latest Social Stream
View Full GRCL Social Stream
Latest GRCL News From Around the Web
Below are the latest news stories about GRACELL BIOTECHNOLOGIES INC that investors may wish to consider to help them evaluate GRCL as an investment opportunity.
We're starting off the week with a look at the biggest pre-market stock movers traders need to know about for Monday morning!
Gracell Biotechnologies Inc (NASDAQ: GRCL) announced the clinical data from its ongoing Phase 1 investigator-initiated trial (IIT) in China evaluating GC012F as first-line therapy in transplant-eligible, high-risk, newly diagnosed multiple myeloma (NDMM) patients. Patients in the study achieved a 100% overall response rate (ORR) and 100% minimal residual disease (MRD) negativity in all dose levels. Related: Gracell Biotech Stock Has Over 100% Upside On Next-Gen CAR-T Platforms, Analyst Claims. A
Gracell Biotechnologies Presents Clinical Data for FasTCAR-T GC012F for High Risk, Newly Diagnosed Multiple Myeloma Demonstrating 100% Overall Response Rate
Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced the clinical data from its ongoing Phase 1, investigator-initiated trial (IIT) in China evaluating FasTCAR-enabled GC012F as first-line therapy in transplant-eligible, high-risk, newly diagnosed multiple myeloma (NDMM) patients. Data has been presented in an
HC Wainwright initiated coverage on Gracell Biotechnologies Inc (NASDAQ: GRCL) with a Buy rating and a price target of $6. The China-based company is focused on developing autologous and allogeneic CART cell therapies to treat cancer. The analyst notes that Gracell will submit an IND for a potentially registrational study in the U.S. for GC012F (lead program) for relapsed/refractory multiple myeloma by year-end. Related: Gracell Reveals Encouraging Data From Pretreated Multiple Myeloma Patients.
Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in and attend one-on-one meetings at two upcoming investor conferences.
GRCL Price Returns